Lyka Labs Stock Prediction 2026: Analyst Target, Forecast and Key Levels
- June 22, 2026
- Posted by: Kunal Singla
- Category: News
NSE: LYKALABS | CMP Rs 68.85. 52W High Rs 121.44. 52W Low Rs 44.1. Base target Rs 79.2. Bull case Rs 88.1.
The Lyka Labs stock prediction for 2026 points to a base case target of Rs 79.2, with a bull case of Rs 88.1 and a bear case of Rs 63.3 based on current fundamentals and sector outlook. Lyka Labs is currently down 43.3% from its 52-week high of Rs 121.44 on the NSE, and analysts are closely tracking its trajectory against the Nifty 50 and Sensex.
This article covers the Lyka Labs stock prediction in detail, including short-term, 12-month, and long-term views, key business drivers, risk factors, and the bull-bear scenario framework that Kunal Singla and Ankit Jaiswal use to evaluate the stock’s risk-reward.
Click Here – Get Free Investment Predictions
Analyst Target Summary for Lyka Labs Stock Prediction 2026
| Parameter | Details |
|---|---|
| NSE Symbol | LYKALABS |
| Company | Lyka Labs |
| Sector | Pharma |
| CMP (Rs) | 68.85 |
| 52-Week High (Rs) | 121.44 |
| 52-Week Low (Rs) | 44.1 |
| Market Cap | N/A |
| P/E Ratio | N/A |
| Base Target 12M (Rs) | 79.2 |
| Bull Case (Rs) | 88.1 |
| Bear Case (Rs) | 63.3 |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has now shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks on Univest
Lyka Labs Company Overview
Lyka Labs (NSE: LYKALABS) is a pharma-sector company listed on the National Stock Exchange of India. The company operates in the pharma space and has established a presence in its respective market through its products and services. Understanding the business model is essential before analysing the Lyka Labs stock prediction.
The stock is tracked by retail and institutional investors who monitor the Nifty Pharma for sector-level cues. With a current market price of Rs 68.85 and a 52-week range of Rs 44.1 to Rs 121.44, Lyka Labs presents a case study in pharma sector dynamics and valuation.
Lyka Labs Stock Prediction Across Time Horizons
Short-Term Lyka Labs Stock Prediction for 3 to 6 Months
In the short term, near-term earnings delivery and broader market sentiment. Kunal Singla notes that Rs 73.0 is a realistic near-term target if earnings momentum holds and FII flows remain supportive of the broader Nifty 50 trajectory.
12-Month Lyka Labs Stock Prediction for 2026
The 12-month Lyka Labs stock prediction stands at Rs 79.2 as the base case, representing roughly 15% upside from the current market price. This target is contingent on sustained earnings growth, margin improvement, and a stable macro backdrop through 2026.
Long-Term Lyka Labs Stock Prediction for FY27 to FY28
Ankit Jaiswal observes that if the company executes on its strategic roadmap, the long-term share price target points toward Rs 96.4 by FY28, assuming compounding earnings growth and a potential sector multiple re-rating.
Key Factors Driving the Lyka Labs Stock Prediction 2026
US Generics Pipeline and ANDA Approvals
A strong pipeline of abbreviated new drug applications (ANDAs) with the US FDA creates medium-term revenue opportunity. Each new approval adds predictable, high-margin generic revenue streams. Kunal Singla watches this factor closely when forming the 2026 share price view.
Domestic Formulations Growth
India’s branded generics market is expanding on the back of rising health insurance penetration and chronic disease burden. Strong domestic volume growth supports revenue stability. Ankit Jaiswal watches this factor closely when forming the 2026 share price view.
API Integration and Cost Efficiency
Backward integration into active pharmaceutical ingredients reduces input cost volatility and improves gross margins. In-house API supply insulates the company from Chinese raw material price shocks. Kunal Singla watches this factor closely when forming the 2026 share price view.
Emerging Market Expansion
Scaling up in underpenetrated markets across Africa, Latin America, and Southeast Asia diversifies revenue away from the highly competitive US generics segment. Ankit Jaiswal watches this factor closely when forming the 2026 share price view.
Bull Case and Bear Case for Lyka Labs Stock Prediction 2026
| Scenario | Target (Rs) | Key Condition |
|---|---|---|
| Bull Case | 88.1 | Strong earnings beat, sector tailwinds, FII inflows |
| Base Case | 79.2 | In-line earnings, stable macro, 15% upside |
| Bear Case | 63.3 | Earnings miss, sector headwinds, risk-off markets |
These scenarios are illustrative and based on broad analyst estimates. They are not a guaranteed return forecast from Univest.
Reading the Lyka Labs Stock Prediction from Analyst Perspective
Kunal Singla notes that the Lyka Labs stock prediction hinges on the company’s ability to maintain earnings growth while managing sector-specific headwinds. The current valuation, with the stock at Rs 68.85, offers a reasonable entry point for investors with a 12 to 24 month horizon.
Ankit Jaiswal observes that investors should track quarterly earnings delivery, management commentary on the demand environment, and movement in the Nifty Pharma before assigning high conviction to the share price forecast. Both analysts suggest that risk management is as important as upside in any stock view.
Key Risks to the Lyka Labs Stock Prediction 2026
US FDA Warning Letters and Import Alerts
Any USFDA observations, import alert, or warning letter at manufacturing facilities can block US shipments and severely impact revenue in the near term. Investors should factor this risk into the 2026 outlook.
Pricing Pressure in US Generics
Structural price erosion in the US generics market, driven by customer consolidation and competition, compresses per-unit realisations year on year. Investors should factor this risk into the 2026 outlook.
Regulatory and Drug Price Control Orders
The Indian government periodically brings more drugs under DPCO price caps, which can cap domestic price increases and squeeze branded formulation margins. Investors should factor this risk into the 2026 outlook.
Raw Material and API Price Volatility
Dependence on Chinese API inputs creates supply chain vulnerability. Any disruption or cost spike in raw materials directly squeezes gross margins. Investors should factor this risk into the 2026 outlook.
How to Monitor the Lyka Labs Stock Prediction
To stay updated on the Lyka Labs stock prediction and track real-time price movements and fundamentals, investors can use verified data platforms.
Use the Univest Screener to track Lyka Labs live price and updated target levels.
Key data points to monitor include quarterly results, promoter shareholding changes, FII and DII flow data, and movement in the Nifty 50 which sets the broad market tone for share prices broadly.
Conclusion
The Lyka Labs stock prediction for 2026 presents a base case of Rs 79.2, a bull case of Rs 88.1, and a bear case of Rs 63.3. These targets are derived from sector fundamentals, earnings trajectory, and macro tailwinds that Kunal Singla and Ankit Jaiswal track across the pharma space.
Investors looking for the best share price target for 2026 should review quarterly earnings, study the bull and bear scenario table, and consult a SEBI-registered advisor before making investment decisions based on any stock prediction.
Download the Univest iOS App or Univest Android App to track Lyka Labs share price live and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Lyka Labs Stock Prediction 2026
What is the Lyka Labs stock prediction for 2026?
Ans. The Lyka Labs stock prediction for 2026 is a base case of Rs 79.2, a bull case of Rs 88.1, and a bear case of Rs 63.3 based on sector fundamentals and earnings outlook.
What is the 12-month Lyka Labs stock forecast?
Ans. The 12-month Lyka Labs stock forecast is Rs 79.2, representing approximately 15% upside from the current market price. This Lyka Labs stock prediction assumes in-line earnings and stable macro conditions through 2026.
What is the Lyka Labs share price target for FY27 and FY28?
Ans. The long-term Lyka Labs stock prediction suggests Rs 96.4 by FY28, contingent on sustained earnings growth and a potential sector re-rating. This is a Lyka Labs stock forecast, not a guaranteed return.
What are the key risks to the Lyka Labs stock prediction?
Ans. Key risks to the Lyka Labs stock prediction include sector-specific headwinds, FII selling pressure, earnings misses relative to expectations, global macro uncertainty, and regulatory changes. Investors should factor these risks into their assessment of any Lyka Labs stock forecast.
Is Lyka Labs a good stock to buy in 2026?
Ans. Whether Lyka Labs is a good stock to buy depends on your investment horizon and risk tolerance. The Lyka Labs stock prediction of Rs 79.2 implies potential upside. Consult a SEBI-registered advisor before investing based on any Lyka Labs stock forecast.
What is the Lyka Labs 52-week high and low?
Ans. The Lyka Labs 52-week high is Rs 121.44 and the 52-week low is Rs 44.1. These levels serve as key reference points when evaluating the Lyka Labs stock prediction.
How do I track the Lyka Labs stock prediction?
Ans. You can track the Lyka Labs stock prediction on the Univest Screener at screeners.univest.in, which provides real-time price data, analyst targets, and fundamental metrics. Verify all price data with the official NSE website before acting on any Lyka Labs stock forecast.
